Skip to main
PSTV

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics is making promising strides in the development and commercialization of complex treatments for patients with cancer and rare diseases, particularly with their main programs targeting recurrent glioblastoma and leptomeningeal metastases. With a strong Q4 performance, a healthy balance sheet, and ongoing activities to push forward pivotal trials and optimize commercial efforts, the company appears to have a solid foundation for future growth and success. However, investors should be wary of potential risks related to the company's clinical and regulatory process, partnerships and financials, commercial success, legal and intellectual property, as well as market competition.

Bears say

Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing treatments for patients with cancer and rare diseases, specifically in the CNS space. While they have some promising products in their pipeline, such as the Rhenium-186-chelated NanoLiposome (Rhenium (186Re) Obisbemeda), there are significant risks to their attainment of commercial success, including competition, changing macroeconomic factors, and regulatory approval. Additionally, the company's recent reverse stock split may signal capital market strain and could take time to repair their shareholder base. Despite advances in their pipeline, these risks contribute to a negative outlook on the company's stock.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.